Overview

Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma

Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
Observe the best dose, efficacy and adverse reactions of BAd in the treatment of relapsed and refractory multiple myeloma.
Phase:
Phase 3
Details
Lead Sponsor:
Liao Aijun
Treatments:
Bendamustine Hydrochloride
Dexamethasone
Doxorubicin
Liposomal doxorubicin